Results 1 to 10 of about 1,239,381 (194)
Blockage of the IL-31 Pathway as a Potential Target Therapy for Atopic Dermatitis [PDF]
Pharmaceutics, 2023 Atopic dermatitis (AD), a pruritic, inflammatory chronic disease with multifactorial pathogenesis, has been a therapeutic challenge. Novel target treatments aim to reduce not only the immunologic dysfunction and microbiome dysbiosis but also the recovery
Raquel Leao Orfali, Valeria Aoki
doaj +2 more sources
The role of IL-31 and IL-34 in the diagnosis and treatment of chronic periodontitis [PDF]
Open Life Sciences, 2023 This study was devoted to demonstrating the role of IL-31 and IL-34 in the diagnosis and treatment of chronic periodontitis (CP). From the results, we found that the IL-31 and IL-34 levels were significantly increased in GCF and serum of CP patients ...
Luo Ying, Ding Yi, Chen Yaduo
doaj +2 more sources
Anti-atopic dermatitis effect of fraxinellone via inhibiting IL-31 in vivo and in vitro [PDF]
HeliyonChronic recurrent itch and skin inflammation are prominent features of atopic dermatitis (AD), which is closely related to the immune response driven by T-helper type 2 (Th2) cells.
Niuniu Yang +6 more
doaj +2 more sources
IL-31 induces antitumor immunity in breast carcinoma [PDF]
Journal for ImmunoTherapy of Cancer, 2020 Background Immunomodulatory agents that induce antitumor immunity have great potential for treatment of cancer. We have previously shown that interleukin (IL)-31, a proinflammatory cytokine from the IL-6 family, acts as an antiangiogenic agent.
Tal Kan +6 more
doaj +2 more sources
IL-5, IL-31 and systemic immune-inflammation index as biomarkers predicting severity and progression in bullous pemphigoid [PDF]
Frontiers in MedicineIntroductionInflammatory mechanisms assume a pivotal role in bullous pemphigoid (BP). IL-31, IL-5, and the systemic immunoinflammatory index (SII) are emerging markers of inflammatory activity, but their associations with BP severity remain unclear. This
Yanyu Zhang +12 more
doaj +2 more sources
Interleukin-31 as a Clinical Target for Pruritus Treatment
Frontiers in Medicine, 2021 In recent years, the published literature has suggested the key involvement of the cytokine interleukin-31 (IL-31) in the symptomatology of pruritus, and both IL-31 and its receptor have become potential therapeutic targets for a range of pruritic ...
Kenji Kabashima, Hiroyuki Irie
doaj +1 more source
Neurobiology of Pain, 2022 To elucidate the mechanisms underlying the antipruritic effect of capsaicin, we investigated how topical application of capsaicin (0.01, 0.1 and 1.0% w/v) affects spontaneous scratching in NC/Nga mice, inerleukin-31 (IL-31) induced in BALB/c mice, and IL-
Iwao Arai +4 more
doaj +1 more source
Interleukin-31 new biomarker of infectious skin diseases
Journal of V. N. Karazin Kharkiv National University: Series Medicine, 2021 Introduction. The introduction of antiretroviral therapy has significantly improved the long-term prognosis of AIDS patients, but opportunistic infections can still be life-threatening for this population.
Diana Dorosh
doaj +1 more source
Molecules, 2021 Rheumatoid arthritis (RA) is an autoimmune inflammatory joint disease with complex pathogenesis associated with cytokine dysregulation. Macrophage migration inhibitory factor (MIF) plays a role in systemic inflammation and joint destruction in RA and ...
Samuel García-Arellano +5 more
doaj +1 more source
Pathogenesis of Atopic Dermatitis: Current Paradigm [PDF]
Iranian Journal of Immunology, 2019 Atopic dermatitis (AD) is characterized by skin inflammation, barrier dysfunction and chronic pruritus. In this review, recent advances in the pathogenesis of AD are summarized.
Masutaka Furue +5 more
doaj +1 more source